DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline ...

Chlorambucil(Leukeran) generic is a cytotoxic chemotherapy drug, prescribed for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and lymphosarcoma. It slows or stops cancer ...

The international, multicenter, open-label, randomized trial compared first-line ibrutinib monotherapy with chlorambucil in 269 previously untreated CLL patients aged 65 years and older without ...

The estimated 30-month PFS rate was 81% in the ibrutinib plus venetoclax arm compared with 36% with chlorambucil plus obinutuzumab. The undetectable MRD (uMRD; assessed by next-generation sequencing ...

Chlorambucil is a cytotoxic chemotherapy drug, prescribed for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and lymphosarcoma. It slows or stops cancer cell growth.

Leukeran (chlorambucil) is a prescription brand-name medication. It’s approved by the Food and Drug Administration (FDA) for palliative treatment of the following types of cancer in adults: ...

A study of the combination of ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab for the first-line treatment of participants with chronic lymphocytic leukemia (CLL) ...

The median exposure to Imbruvica plus Venclexta was 13.8 months compared with 5.1 months for chlorambucil plus obinutuzumab. “Safety profiles for both arms were as expected given the known safety ...

Results of the CLL14 trial, which were presented today at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois, resulted in the approval of the venetoclax ...

The percentages of patients with minimal residual disease negativity in the chlorambucil–obinutuzumab group in the current trial (35.2% in peripheral blood and 17.1% in bone marrow) were similar ...